Evidence map›Paper›PMID 31838790›Full record

ArticleCellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology2019

Schlafen12 Reduces the Aggressiveness of Triple Negative Breast Cancer through Post-Transcriptional Regulation of ZEB1 That Drives Stem Cell Differentiation.

Sarmad Al-Marsoummi, Emilie Vomhof-DeKrey, Marc D Basson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sarmad Al-MarsoummiDepartment of Biomedical Sciences, University of North Dakota School of Medicine and the Health Sciences, Grand Forks, ND, USA.
Emilie Vomhof-DeKreyDepartment of Biomedical Sciences, University of North Dakota School of Medicine and the Health Sciences, Grand Forks, ND, USA.
Marc D BassonDepartment of Biomedical Sciences, University of North Dakota School of Medicine and the Health Sciences, Grand Forks, ND, USA, marc.basson@und.edu.
University of North Dakota · US

Funding

Research CoresP20GM103442 · NIGMS · UNIVERSITY OF NORTH DAKOTA · PI Donald A. Sens · 2012 to 2026
$53.0M
WORKSHOPS AND EVALUATIONP20RR016471 · NCRR · UNIVERSITY OF NORTH DAKOTA · PI DELORME, EUGENE L. · 2001 to 2011
$31.7M
Yersina perstis interactions with macrophagesP20GM113123 · NIGMS · UNIVERSITY OF NORTH DAKOTA · PI COMBS, COLIN K · 2016 to 2025
$19.9M
Schlafen mediation of intestinal differentiationR01DK096137 · NIDDK · UNIVERSITY OF NORTH DAKOTA · PI BASSON, MARC D. · 2014 to 2017
$1.5M
NCRR NIH HHS P20 RR016471NIDDK NIH HHS R01 DK096137NIGMS NIH HHS P20 GM103442NIGMS NIH HHS P20 GM113123NIH (National Institutes of Health) RO1 DK096137, P20GM103442, P20GM113123
6 · The paper itself

Abstract

BACKGROUND/

aimsSchlafen12 (SLFN12) promotes human intestinal and prostatic epithelial differentiation. We sought to determine whether SLFN12 reduces triple-negative breast cancer (TNBC) aggressiveness.

methodsWe validated bioinformatics analyses of publicly available databases by staining human TNBC. After virally overexpressing or siRNA-reducing SLFN12 in TNBC cell lines, we measured proliferation by CCK-8 assay, invasion into basement-membrane-coated pores, mRNA by q-RT-PCR and protein by Western blotting. Flow cytometry assessed proliferation and stem cell marker expression, and sorted CD44+/CD24- cells. Stemness was also assessed by mammosphere formation, and translation by click-it-AHA chemistry.

resultsSLFN12 expression was lower in TNBC tumors and correlated with survival. SLFN12 overexpression reduced TNBC MDA-MB-231, BT549, and Hs578T proliferation. In MDA-MB-231 cells, AdSLFN12 reduced invasion, promoted cell cycle arrest, increased E-cadherin promoter activity, mRNA, and protein, and reduced vimentin expression and protein. SLFN12 knockdown increased vimentin. AdSLFN12 reduced the proportion of MDA-MB-231 CD44

conclusionSLFN12 may reduce TNBC aggressiveness and improve survival in part by a post-transcriptional decrease in ZEB1 that promotes TNBC cancer stem cell differentiation.

Indexed as

Cell DifferentiationCadherinsCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansIntracellular Signaling Peptides and ProteinsNeoplastic Stem CellsRNA InterferenceRNA, Small InterferingSnail Family Transcription FactorsSurvival RateTriple Negative Breast NeoplasmsZinc Finger E-box-Binding Homeobox 1CadherinsIntracellular Signaling Peptides and ProteinsRNA, Small InterferingSLFN12 protein, humanSNAI1 protein, humanSnail Family Transcription FactorsZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1Schlafen12; TNBC; Breast cancer stem cell; Differentiation

Identifiers

PMID31838790
PMCPMC7007982
OpenAlexW3006038988

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.